23144, P = 0.0615, n = 66).

In both a and b, the regression lines for normotensive and hypertensive patients were not considered to be identical, with different R428 cell line y-intercepts, since there was a significant difference (P < 0.01, F test) in the y-intercept of the two regression lines under the null hypothesis that the y-intercept of two lines was identical. There was no significant difference (P = 0.6061 in a or P = 0.6079 in b, F test) in the slope of the two lines under the null hypothesis that the slope of the two lines was identical Table 4 shows that in young adult patients aged <36 years, eGFR was lower and TKV was larger in the hypertensive group than in the normal blood pressure group. Table 4 Comparison of eGFR and TKV between normal and high blood pressure groups in young adults (≤35 years)   Normotensive group Hypertensive group P value N 36 27   Initial BPa  Systolic (mmHg) 117.9 ± 15.1 148.1 ± 14.2 <0.0001  Diastolic (mmHg) 68.5 ± 6.9 85.9 ± 13.7 0.0001 Post-Tx BPb  Systolic (mmHg) 115.8 ± 14.4 128.4 ± 12.9 0.0030  Diastolic (mmHg) 70.5 ± 11.6

78.4 ± 6.5 0.0066 eGFR (ml/min/1.73 m2) 113.6 ± 42.5 86.6 ± 24.2 0.0044 N 10 12   TKV (ml) 826.3 ± 319.2 1713.2 ± 675.6 0.0011 Data are the mean ± SD. P values were calculated by Student’s t test aInitial BP is blood Selleck Fulvestrant pressure without anti-hypertensive treatment in hypertensive group and blood pressure at initial visit in normotensive group bPost-Tx BP is blood pressure at the study time. In hypertensive group, all patients were receiving antihypertensive medication Discussion ADPKD is the most common hereditary kidney disease. The disease is characterized by the formation of numerous kidney cysts and their development, leading to kidney enlargement and failure, reaching end-stage renal failure in up to about 50% by age 70 [16]. Polycystic kidney disease animal model studies suggested that earlier intervention resulted in more effective prevention of disease progression [17, 18]. The potential candidates

clinically examined so far seem Anacetrapib to attenuate progression but not to reverse progressed renal disease [6–8, 11]. Thus, it is a crucial issue when to start treatment intervention. The present study confirmed that renal function decreased progressively as a function of age [1, 3, 16, 19, 20]. In 196 patients with a mean age >30 years, the mean eGFR slope was −3.4 ± 4.9 ml/min/1.73 m2/year. In 46 patients with mean TKV >1500 ml, the TKV slope was 86.8 ± 161.6 ml/year (5.6 ± 8.8%/year) (Table 1). The present data of eGFR and TKV slopes are compatible with previous findings [3, 10]. The slopes of GFR (measured by iothalamate clearance) and TKV were analyzed according to TKV and age groups in the CRISP study [3]. Analysis of variance revealed that the slopes of GFR differed among subgroups with different initial TKV (P = 0.005), whereas the slopes of GFR did not differ significantly among subgroups with different initial ages (P = 0.20); there was no significant interaction between TKV and age (P = 0.